The lawsuit claims GlaxoSmithKline replaced Flovent ... the lawsuit says, "GSK put corporate greed ahead of the health and safety of Arizona's families and children," Mayes said in a news release.
TipRanks on MSN23h
GSK Executives Involved in Share Vesting and SalesGSK announced several transactions involving the vesting and sale of ordinary shares under its Performance Share Plan and Deferred Investment Award Programme. The transactions involve key executives, ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.
The lawsuit filed in Maricopa County Superior Court contends GlaxoSmithKline's actions violate the Arizona Consumer Fraud Act ...
CORE EARNINGS PER SHARE FORECAST: Fourth-quarter core earnings per share is expected to fall to 20.6 pounds from 28.9 pounds the year earlier, according to Visible Alpha. Shares in GSK are 3.6% up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback